Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05687994 · ClinicalTrials.gov registry record · NA
Speech Entrainment Treatment for People With Aphasia
A NA study, sponsored by Albert Einstein Healthcare Network.
- Completed
- Registry status
- NA
- Development phase
- 30
- Enrollment target
NCT05687994: Completed NA study, sponsored by Albert Einstein Healthcare Network.
NCT05687994 is a NA study that has completed, run by Albert Einstein Healthcare Network. The registered enrollment target is 30 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05687994, a NA study, has completed, sponsored by Albert Einstein Healthcare Network.
- COMPLETED
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
Study Summary
The objective of this research is to experimentally delineate the direct effect of speech entrainment practice on independent speech production and identify practice conditions that enhance treatment benefits. The primary outcome measure (Correct Information Units per minute) tallies informativeness and efficiency of independent speech in treated stories.
Primary Outcome
Correct Information Units per Minute will be tallied by blinded coders to measure the informativeness and efficacy of speech
Interventions
- BEHAVIORAL Audiovisual Speech Entrainment Practice
- BEHAVIORAL Auditory Speech Entrainment Practice
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2023-01-25 |
| Est. Completion | 2025-05-29 |
| Phase | NA |
What the finished NCT05687994 record still lists
NCT05687994 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 2 interventions - of which Audiovisual Speech Entrainment Practice is the first listed.
NCT05687994 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05687994 about?
NCT05687994 is a clinical study titled "Speech Entrainment Treatment for People With Aphasia". The objective of this research is to experimentally delineate the direct effect of speech entrainment practice on independent speech production and identify practice conditions that enhance treatment benefits. The primary outcome measure (Correct Information Units per minute) tallies informativeness...
What is the current status of trial NCT05687994?
This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2023-01-25. Estimated completion is 2025-05-29.
What interventions are being tested in trial NCT05687994?
The interventions under investigation include: Audiovisual Speech Entrainment Practice (BEHAVIORAL), Auditory Speech Entrainment Practice (BEHAVIORAL).
Who is sponsoring clinical trial NCT05687994?
This trial is sponsored by Albert Einstein Healthcare Network, which has 48 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05687994's enrollment target sits among peer trials
30 1593rd of 2000 higher than 299 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI